Balyasny Asset Management LLC Citius Pharmaceuticals, Inc. Transaction History
Balyasny Asset Management LLC
- $54.9 Billion
- Q2 2024
A detailed history of Balyasny Asset Management LLC transactions in Citius Pharmaceuticals, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 27,053 shares of CTXR stock, worth $14,067. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27,053Holding current value
$14,067% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CTXR
# of Institutions
73Shares Held
30.6MCall Options Held
24.7KPut Options Held
0-
Armistice Capital, LLC New York, NY10.2MShares$5.28 Million0.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.33MShares$3.29 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.05MShares$1.07 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.81MShares$938,9770.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.65MShares$856,0740.0% of portfolio
About Citius Pharmaceuticals, Inc.
- Ticker CTXR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 146,130,000
- Market Cap $76M
- Description
- Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...